IDH2 and chondrosarcoma: Apart from solid malignancies which typically harbor IDH1/2 mutations as leading driver mutations (gliomas, iCCAs, chondrosarcoma, and SNUCs), many other solid tumors develop IDH mutations as a late event during disease progression [127,146,147,148,149,150].